All HEI'sAthlone Institute of TechnologyCork Institute of TechnologyDublin City UniversityDublin Institute of TechnologyMaynooth UniversityNational University of Ireland, GalwayRoyal College of SurgeonsTeagascTrinity College DublinUniversity College CorkUniversity College DublinUniversity of LimerickWaterford Institute of Technology All SectorsFuture Networks and CommunicationsData Analytics, Management, Security and PrivacyDigital Platforms, Content and ApplicationsConnected Health and Independent LivingMedical DevicesDiagnosticsTherapeutics - Synthesis, Formulation, Processing and Drug DeliveryFood for HealthSustainable Food Production and ProcessingMarine and Renewable EnergySmart Grids and Smart CitiesManufacturing CompetitivenessProcessing Technologies and Novel MaterialsInnovation in Services and Business ProcessesepiCaPture - A new urine test to detect high-risk prostate cancer- Licensing Opportunity from Trinity College Dublin - July 2015A urine test that detects the presence of prostate cancer cells and measures biochemical changes at 6 genes. It Identifies which men need a biopsy to diagnose prostate cancer and also uses an algorithm to assess prostat... pdf 1.2MBBiomarker for Colorectal Cancer - Licensing Opportunity from Trinity College Dublin - July 2015The pathogenesis of 15% of human cancers has been linked to inflammation. One of the most prevalent inflammation driven cancers is colitis-associated colorectal cancer (CRC). Annually Ireland - CRC is responsible for 15%... pdf 1MBDissolution Simulation - Licensing Opportunity from Trinity College Dublin - July 2015This software code allows generation of a simulated profile of particles dissolving over time. It includes simulation of dissolution under a range of pharmaceutical industry-standard test conditions.pdf 1.1MBCartilage Repair Therapy - Licensing Opportunity from Trinity College Dublin - July 2015Articular cartilage injury or degeneration is a common disorder of joints, affecting people of all ages. More than 500,000 cartilage repair procedures are performed annually in the United States alone. The intrinsic rang... pdf 1.1MBNovel Biomarker for Multiple Myeloma Diagnosis and Prognosis - Licensing Opportunity from National University of Ireland Galway - March 2015Multiple Myeloma is a highly prevalent disease accounting for 1-2% of all cancers, with a market size for treatments estimated to grow to $7 billion by 2020. This technology will prove to be extremely valuable in fightin... pdf 1.2MB First 1234567891011121314151617181920212223 Last Print Bookmark Top